Vmn1r221 inhibitors are chemical compounds that target and inhibit the activity of the Vmn1r221 receptor. The Vmn1r221 receptor is part of the Vomeronasal type-1 receptor (Vmn1r) family, which is a large group of G-protein-coupled receptors (GPCRs) primarily involved in detecting pheromones and chemical signals in certain species. This receptor is expressed in the vomeronasal organ (VNO), which is responsible for the detection of chemical cues essential for social and reproductive behaviors in animals. The structure of Vmn1r221 inhibitors is often tailored to fit the binding site of the receptor, blocking the interaction between Vmn1r221 and its natural ligands. These inhibitors are important tools for studying the biological processes mediated by the Vmn1r family and for understanding how chemical signaling pathways are regulated.
The design of Vmn1r221 inhibitors involves a combination of computational modeling and structural biology to predict how these compounds will interact with the receptor. Inhibitors may vary in size, polarity, and molecular flexibility, depending on the specific characteristics of the Vmn1r221 receptor's active site. These compounds are commonly used in biochemical assays to dissect the role of Vmn1r221 in cell signaling, protein interactions, and receptor activation. Furthermore, they provide valuable insight into the molecular architecture of GPCR receptors and how ligand binding can influence receptor conformation and function. By modulating the activity of Vmn1r221, these inhibitors serve as essential tools for research in receptor biology, signaling cascades, and the broader field of chemical communication within organisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol 525-66-6 Beta-adrenergic receptor antagonist that can modulate GPCR signaling, possibly affecting Vmn1r221 indirectly. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine 51481-61-9 Histamine H2 receptor antagonist, may alter GPCR-mediated processes, potentially impacting Vmn1r221. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Ondansetron 99614-02-5 Serotonin receptor antagonist, might affect GPCR signaling pathways, influencing Vmn1r221 indirectly. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin 66575-29-9 Activates adenylate cyclase, increasing cAMP levels which could modulate GPCR signaling affecting Vmn1r221. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker, could affect calcium signaling pathways, potentially related to Vmn1r221. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin 19545-26-7 PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r221 function. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Haloperidol 52-86-8 Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r221. | ||||||